Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729677 · ClinicalTrials.gov registry record
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
A clinical trial, sponsored by Beth Israel Medical Center.
- Completed
- Registry status
- 64
- Enrollment target
NCT00729677: Completed study, sponsored by Beth Israel Medical Center.
NCT00729677 is a clinical trial that has completed, run by Beth Israel Medical Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00729677 has completed, sponsored by Beth Israel Medical Center.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients' quality of life. PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-vomiting medicine during the first course of chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-12 |
What the finished NCT00729677 record still lists
NCT00729677 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00729677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00729677 about?
NCT00729677 is a clinical study titled "Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin". RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients' quality of life. PURPOSE: This clinical trial is studying delayed nausea and vomiting in p...
What is the current status of trial NCT00729677?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2005-06. Estimated completion is 2008-12.
Who is sponsoring clinical trial NCT00729677?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia